Safety of guselkumab in hepatitis B virus infection
نام عام مواد
[Article]
نام نخستين پديدآور
Duncan, James Robert; Orlowski, Timothy J.; Elewski, Boni E.
یادداشتهای مربوط به خلاصه یا چکیده
متن يادداشت
Reactivation of hepatitis B virus (HBV) following the use of TNF antagonists has been reported and is a contraindication to use of these medications. Although the risk of reactivation of HBV during use of ustekinumab and secukinumab is low in patients with only HBV core antibody positivity, the risk is substantial in patients with chronic HBV infection. Less information is available regarding the use of pure IL-23 antagonists. Herein we discuss the successful treatment with guselkumab of a patient with HBV core antibody positivity, without evidence of HBV reactivation or other liver complications.
مجموعه
تاريخ نشر
2019
عنوان
Dermatology Online Journal
شماره جلد
25/10
نام شخص به منزله سر شناسه - (مسئولیت معنوی درجه اول )
عنصر شناسه اي
Duncan, James Robert; Orlowski, Timothy J.; Elewski, Boni E.